Gvazava I G, Kosykh A V, Rogovaya O S, Popova O P, Sobyanin K A, Khrushchev A C, Timofeev A V, Vorotelyak E A
Koltsov Institute of Developmental Biology, Russian Academy of Sciences, Moscow, 119334 Russia.
Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow, 117997 Russia.
Acta Naturae. 2020 Oct-Dec;12(4):98-104. doi: 10.32607/actanaturae.11202.
Preclinical studies of human cellular and tissue-based products (HCT/Ps) for transplantation therapy of type 1 diabetes mellitus (T1DM) necessarily involve animal models, particularly mouse models of diabetes induced by streptozotocin (STZ). These models should mimic the clinical and metabolic manifestations of T1DM in humans (face validity) and be similar to T1DM in terms of the pathogenetic mechanism (construct validity). Furthermore, since HCT/Ps contain human cells, modeling of diabetes in immune-deficient animals is obligatory. Here we describe the most simplified diabetes model in Nude mice. Diabetes was induced in 31 males by a single intraperitoneal injection of STZ in normal saline at a medium-to-high dose of 150 mg/kg body weight. Fourteen control animals received only saline. Non-fasting plasma glucose (PG) levels were measured periodically for 50 days. All STZ-treated mice survived beyond 50 days. By day 15 after STZ administration, 22 of 31 (71%) mice developed stable diabetes based on the following criteria: (1) non-fasting PG ≥ 15 mmol/L on consecutive measurements up until day 50; (2) no diabetes remission. The mean non-fasting PG in mice with stable diabetes over the period of 35 days was equal to 25.7 mmol/L. On day 50, mean plasma insulin concentration, mean pancreatic insulin content, and the average number of β-cells in pancreatic islets were 2.6, 8.4, and 50 times lower, respectively, than in the control animals. We consider that our Nude mouse model of diabetes meets face validity and construct validity criteria and can be used in preclinical studies of HCT/Ps.
用于 1 型糖尿病(T1DM)移植治疗的基于人细胞和组织的产品(HCT/Ps)的临床前研究必然涉及动物模型,尤其是链脲佐菌素(STZ)诱导的糖尿病小鼠模型。这些模型应模拟人类 T1DM 的临床和代谢表现(表面效度),并在发病机制方面与 T1DM 相似(结构效度)。此外,由于 HCT/Ps 包含人类细胞,在免疫缺陷动物中建立糖尿病模型是必不可少的。在此,我们描述了裸鼠中最简化的糖尿病模型。通过以 150 mg/kg 体重的中高剂量腹腔注射一次溶解于生理盐水中的 STZ,诱导 31 只雄性裸鼠患糖尿病。14 只对照动物仅接受生理盐水。在 50 天内定期测量非空腹血糖(PG)水平。所有接受 STZ 治疗的小鼠存活超过 50 天。在给予 STZ 后第 15 天,31 只小鼠中有 22 只(71%)基于以下标准发展为稳定的糖尿病:(1)直到第 50 天连续测量的非空腹 PG≥15 mmol/L;(2)无糖尿病缓解。在 35 天期间,患有稳定糖尿病的小鼠的平均非空腹 PG 等于 25.7 mmol/L。在第 50 天,平均血浆胰岛素浓度、平均胰腺胰岛素含量以及胰岛中β细胞的平均数量分别比对照动物低 2.6 倍、8.4 倍和 50 倍。我们认为我们的裸鼠糖尿病模型符合表面效度和结构效度标准,可用于 HCT/Ps 的临床前研究。